Fibroblast growth factor 21 (FGF21) analogs are in development for metabolic dysfunction‐associated steatotic liver disease (MASLD), but their impact on problematic alcohol use (PAU), alcohol use disorder (AUD), binge drinking, and alcohol‐related liver disease (ARLD) is unknown.
Fibroblast growth factor 21 (FGF21) analogs are in development for metabolic dysfunction‐associated steatotic liver disease (MASLD), but their impact on problematic alcohol use (PAU), alcohol use disorder (AUD), binge drinking, and alcohol‐related liver disease (ARLD) is unknown.